<DOC>
	<DOCNO>NCT01893788</DOCNO>
	<brief_summary>The primary objective study determine treatment effective reduce leave ventricular mass hypertensive patient leave ventricular hypertrophy compare aliskiren eplerenone .</brief_summary>
	<brief_title>Eplerenone Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Male female ≧ 20 year age Clinical diagnosis hypertension Patients able provide write informed consent 1 . History congestive heart failure , myocardial infarction , coronary revascularization recent 6 month . 2 . Planned take percutaneous coronary intervention coronary artery bypass graft 3 . Severe hypertension ( ≧ 180/110 mmHg ) secondary hypertension malignant hypertension . 4 . History stroke , cerebral hemorrhage , subarachnoid hemorrhage , transient ischemic attack recent 6 month 5 . Severe valvular heart disease atrial fibrillation 6 . Congenital heart disease 7 . Severe heart failure ( NYHA functional class Ⅳ ) 8 . Current treatment aliskiren eplerenone diuretic 9 . Taking potassium preparation potassiumsparing diuretic 10 . Estimated GFR ≦ 30ml/min/1.73m２ screen current treatment hemodialysis 11 . Potassium &gt; 5.0mEq/L screen 12 . Diabetes mellitus microalbuminuria albuminuria 13 . Impairment liver function ( liver failure , liver cirrhosis ) 14 . Pregnant woman possibly pregnant woman 15 . History malignant tumor include hematological neoplasm 16 . Current treatment itraconazole , cyclosporin , ritonavir nelfinavir 17 . Prior treatment , hypersensitivity , intolerance contraindication aliskiren and/or eplerenone 18 . Current participation another clinical trial 19 . Serious noncardiovascular disease severely limit life expectancy 20 . Contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>hypertension</keyword>
	<keyword>leave ventricular hypertrophy</keyword>
	<keyword>renin angiotensin system</keyword>
	<keyword>aldosterone</keyword>
	<keyword>aliskiren</keyword>
	<keyword>eplerenone</keyword>
	<keyword>P3NP</keyword>
</DOC>